Molecule intelOpportunity: Moderate0Crowded market

Chlorpheniramine

232 brands · 141 companies · product forms

5 DRAP alerts

Opportunity snapshot

Launch attractiveness

Market saturation

100

Price room

100

Regulatory risk

232

brands

141

companies

Rs 160.75

median price

price points

33.58x

price spread

confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 2%

REGENT LABORATORIES LTD.

5 brands · 2%

IRZA PHARMA (PVT) LTD.

5 brands · 2%

ALLIANCE PHARMACEUTICALS (PVT) LTD.

5 brands · 2%

EPLA LABORATORIES (PVT) LTD.

4 brands · 2%

PACIFIC PHARMACEUTICALS LTD.

4 brands · 2%

LISKO PAKISTAN (PVT) LTD

4 brands · 2%

KRKA-PAK PHARMACEUTICAL & CHEMICAL WORKS

4 brands · 2%

Pharmatec Pakistan (Pvt.) Limited

4 brands · 2%

Albro Pharmaceuticals

4 brands · 2%

EURO PHARMA INTERNATIONAL

3 brands · 1%

Price room

Across observed sources and strengths

CheapestRs 16.71

MedianRs 160.75

Most expensiveRs 561.11

Spread33.58×

Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 33.58x across 32 trusted points (Rs 16.71-561.11). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Chlorpheniramine — each links to its own medicine page.

Regulatory alerts

Recall exposurelatest 2023-10-26

Drug Product Recall: Tempramine Suspension (Batch # 5TR131) By M/S W. Woodward Pakistan (P

Drug Product Recall: Tempramine Suspension (Batch#5TR057) By M/S W.Woodward Pakistan (Pvt.

Recall Alert: Drug Product; Kemodryl Cough Syrup (Batch # K-1068) by Alkemy Pharmaceutical

Drug Product Recall: Tempramine Suspension (Batch# 5TR052) By M/S W.Woodward Pakistan (Pvt

Drug Product Recall: Tempramine Suspension (Batch # 5TE049) By M/s W.Woodward Pakistan (Pv

Why this score

Launch attractiveness

40% supply-gap(20) + 25% price-variation(100) + 20% low-competition(0) + 15% supply-disruption(40), damped by confidence(90). Higher = more attractive, less crowded opportunity.

Market saturation

141 canonical companies and 232 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 33.58x across 32 trusted points (Rs 16.71-561.11). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

5 DRAP alert(s), latest 2023-10-26 incl. recall/safety.

Confidence

Reduced by: no ATC code.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules